Barclays PLC C4 Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 243,457 shares of CCCC stock, worth $961,655. This represents 0.0% of its overall portfolio holdings.

Number of Shares

243,457

Previous 243,457 -0.0%

Holding current value

$961,655

Previous $1.39 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$4.43 - $7.38 $299,228 - $498,489	67,546 Added 38.4%	243,457 $1.39 Million
Q2 2024 Aug 14, 2024	BUY	$4.05 - $8.1 $497,412 - $994,825	122,818 Added 231.33%	175,911 $812,000
Q1 2024 May 15, 2024	BUY	$5.3 - $11.0 $50,233 - $104,258	9,478 Added 21.73%	53,093 $434,000
Q4 2023 Feb 15, 2024	BUY	$1.18 - $6.03 $1 - $6	1 Added 0.0%	43,615 $247,000
Q3 2023 Nov 07, 2023	BUY	$1.81 - $3.89 $18,545 - $39,856	10,246 Added 30.71%	43,614 $81,000
Q2 2023 Aug 03, 2023	SELL	$2.75 - $3.77 $38,486 - $52,761	-13,995 Reduced 29.55%	33,368 $92,000
Q1 2023 May 04, 2023	SELL	$3.1 - $9.02 $174,483 - $507,690	-56,285 Reduced 54.3%	47,363 $148,000
Q4 2022 Feb 13, 2023	BUY	$5.42 - $10.24 $153,971 - $290,897	28,408 Added 37.76%	103,648 $611,000
Q3 2022 Nov 03, 2022	BUY	$8.03 - $12.77 $572,089 - $909,785	71,244 Added 1782.88%	75,240 $660,000
Q2 2022 Aug 12, 2022	SELL	$5.06 - $26.46 $119,653 - $625,699	-23,647 Reduced 85.54%	3,996 $30,000
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $552,583 - $918,576	27,643 New	27,643 $670,000

Others Institutions Holding CCCC

# of Institutions

130

Shares Held

63.5M

Call Options Held

670K

Put Options Held

54.8K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $193M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account